As CAR-Ts Proliferate, CMS Seeks To Reserve Medicare Add-On Payments For ‘New’ Therapies

Products from Bristol-Myers Squibb, Gilead and J&J might be eligible for supplemental reimbursement under hospital payment proposed rule that could help promote uptake.

New Phase Of Medicare Reimbursement Policy For CAR-T Therapies • Source: Alamy

Two recently-approved CAR-T therapies for lymphoma, Bristol Myers Squibb Company’s Breyanzi and Gilead Sciences, Inc.’s Tecartus, face challenges in getting approval for supplemental Medicare reimbursement as novel agents because their indications could be considered the same or similar to older CAR-Ts.

The Centers for Medicare and Medicaid Services discussed applications for new technology add-on payments for Breyanzi (lisocabtagene maraleucel), Tecartus (brexucabtagene...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Cell & Gene Therapies

More from Advanced Technologies